Table 1.

Recurrent loss or mutation of ARID1A in primary human cancers

Primary cancersARID1A mutation (%)Homozygous (%)Decreased transcript (%)Decreased/absent protein (%)Reference
Ovarian clear-cell carcinoma55/119 (46%)12/55 (22%)N/A27/37 (73%)5
24/42 (57%)11/24 (46%)N/AN/A4
Gastric cancer32/109 (29%)14/32 (44%)N/A24/32 (75%)8
9/110 (8%)2/9 (22%)N/A6/8 (75%)9
10/100 (10%)N/AN/AN/A15
N/AN/AN/A26/180 (14%)6
N/AN/AN/A5/45 (11%)7
N/AN/AN/A95/657 (14%)10
Hepatocellular carcinoma21/125 (17%)1/21 (5%)N/AN/A11
14/110 (13%)N/AN/AN/A13
12/120 (10%)N/AN/AN/A12
N/AN/AN/A0/41 (0%)4
Breast cancer90/256 (35%)a5/90 (6%)Deletions associated with decreased expressionN/A59
4/114 (4%)N/AN/AN/A15
11/82 (13%)a0/11 (0%)N/A240/376 (64%)14
N/AN/A22/40 (55%)63/112 (56%)24
N/AN/AN/A11/315 (3%)6
N/AN/AN/A1/91 (1%)7
N/AN/A5/50 (10%)N/A20
Uterine endometrioid carcinomaN/AN/AN/A90/309 (29%)6
N/AN/AN/A15/58 (26%)7
Uterine clear-cell carcinomaN/AN/AN/A6/23 (26%)6
Pancreatic cancer33/70 (47%)a, tumor + cell lines2/24 (8%)N/AN/A16
10/119 (8%)N/AN/AN/A15
14/39 (36%)1/14 (7%)N/AN/A17
N/AN/AN/A5/85 (6%)6
N/AN/AN/A4/48 (8%)7
Transitional-cell carcinoma of bladder13/97 (13%)N/AN/AN/A18
Waldenström macroglobulinemia5/30 (17%)N/AN/AN/A19
Anaplastic thyroid cancerN/AN/AN/A5/35 (14%)6
Renal cancerN/AN/A6/20 (30%)N/A20
N/AN/AN/A1/58 (2%)6
N/AN/AN/A0/73 (0%)7
Colon cancer12/119 (10%)N/AN/AN/A15
N/AN/A2/30 (7%)N/A20
N/AN/AN/A2/49 (4%)7
N/AN/AN/A1/130 (0.8%)6
Lung cancer2/36 (6%)N/AN/AN/A15
N/AN/A1/21 (5%)N/A20
N/AN/AN/A2/52 (4%)7
N/AN/AN/A12/523 (2%)6
Cervical adenocarcinomaN/AN/AN/A1/11 (9%)7
Bile duct cancerN/AN/AN/A2/27 (7%)7
Prostate cancer2/23 (8%)N/AN/AN/A15
Medulloblastoma3/125 (2%)N/AN/AN/A15

Abbreviation: N/A, not applicable.

  • aARID1A loss via chromosomal deletion.